10X Genomics Inc
NASDAQ:TXG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
10X Genomics Inc
10X Genomics Inc. stands as a beacon of innovation in the rapidly evolving field of genomics, where the frontier of scientific discovery meets commercial enterprise. Founded in 2012, the company emerged from a vision to delve deeper into the cellular universe, offering tools that illuminate the complexities of biological systems. Nestled in the heart of Silicon Valley, the company has harnessed cutting-edge technology to develop platforms that enable scientists to observe cellular behavior with unprecedented clarity and detail. These tools are particularly vital for understanding the nuances of diseases and developing more targeted therapeutic interventions. At its core, 10X Genomics specializes in creating sophisticated single-cell and spatial analysis solutions, which allow researchers to dissect the minutiae of genetic information within individual cells—an advancement that traditional bulk sequencing techniques simply cannot achieve.
This innovative approach is not just a scientific marvel but a robust business model that thrives on the burgeoning demand for advanced genomic research. 10X Genomics generates revenue through a blend of product sales and services. Its primary offerings include instruments and proprietary consumables, such as reagent kits that are fundamental to extracting actionable insights from genomic data. The company’s unique Chromium and Visium platforms are sought after by academic institutions, pharmaceutical companies, and clinical research organizations worldwide. By coupling high-margin consumables with sophisticated hardware, 10X Genomics ensures a recurring revenue stream that supports sustained growth. Meanwhile, it continues to invest heavily in research and development, ensuring its place at the cutting edge of genomic science and maintaining a competitive advantage in a space that demands relentless innovation.
10X Genomics Inc. stands as a beacon of innovation in the rapidly evolving field of genomics, where the frontier of scientific discovery meets commercial enterprise. Founded in 2012, the company emerged from a vision to delve deeper into the cellular universe, offering tools that illuminate the complexities of biological systems. Nestled in the heart of Silicon Valley, the company has harnessed cutting-edge technology to develop platforms that enable scientists to observe cellular behavior with unprecedented clarity and detail. These tools are particularly vital for understanding the nuances of diseases and developing more targeted therapeutic interventions. At its core, 10X Genomics specializes in creating sophisticated single-cell and spatial analysis solutions, which allow researchers to dissect the minutiae of genetic information within individual cells—an advancement that traditional bulk sequencing techniques simply cannot achieve.
This innovative approach is not just a scientific marvel but a robust business model that thrives on the burgeoning demand for advanced genomic research. 10X Genomics generates revenue through a blend of product sales and services. Its primary offerings include instruments and proprietary consumables, such as reagent kits that are fundamental to extracting actionable insights from genomic data. The company’s unique Chromium and Visium platforms are sought after by academic institutions, pharmaceutical companies, and clinical research organizations worldwide. By coupling high-margin consumables with sophisticated hardware, 10X Genomics ensures a recurring revenue stream that supports sustained growth. Meanwhile, it continues to invest heavily in research and development, ensuring its place at the cutting edge of genomic science and maintaining a competitive advantage in a space that demands relentless innovation.
Revenue Beat: 10X Genomics reported Q3 revenue of $149 million, exceeding the top end of guidance, but down 2% year-over-year.
Spatial Strength: Spatial consumables revenue grew 19%, driven by strong Xenium demand and double-digit growth in runs and average spend per run.
Single-Cell Dynamics: Single-cell consumables volume (Chromium) grew double digits, but revenue declined 4% due to lower average selling prices.
Instruments Weakness: Instrument revenue fell sharply, with total instruments down 37% year-over-year amid cautious customer spending and pricing pressure.
Margins & Cost: Gross margin dropped to 67% from 70% last year, primarily due to product mix and inventory write-downs.
Cash Position: Ended Q3 with $482 million in cash, up $35 million sequentially, supporting innovation and long-term investments.
Q4 Guidance: Q4 revenue expected between $154–158 million, a 5% sequential increase, with some instrument uptick factored in and no year-end budget flush expected.
Macro Uncertainty: Management expects spending caution to persist, especially in academic, government, and pharma sectors, and is not providing 2026 guidance.
